Related Experiment Video
Updated: Jan 30, 2026

Author Spotlight: Investigating Liver Cancer Pathogenesis Using Patient-Derived Organoids
Published on: August 18, 2023
Microtubule-targeting agents in oncology and therapeutic potential in hepatocellular carcinoma
1Department of Clinical Oncology, Sir YK Pao Centre for Cancer, Hong Kong Cancer Institute, State Key Laboratory in Oncology in South China, Faculty of Medicine, The Chinese University of Hong Kong, Shatin, NT, Hong Kong.
Abstract:
In mammalian cells, microtubules are present both in interphase and dividing cells. In the latter, microtubules forming the mitotic spindle are highly dynamic and exquisitely sensitive to therapeutic inhibitors. Developed to alter microtubule function, microtubule-binding agents have been proven to be highly active as an anticancer treatment. Significant development of microtubule-binding agents has taken place in recent years, with newer anti-tubulin agents now showing novel properties of enhanced tumor specificity, reduced neurotoxicity, and insensitivity to chemoresistance mechanisms. Hepatocellular carcinoma remains one of the most difficult cancers to treat, with chemotherapies being relatively ineffective. There is now evidence to suggest that microtubule-binding agents may be effective in the treatment of hepatocellular carcinoma, especially when used in combination with mammalian target of rapamycin inhibitors. Preclinical models have suggested that the latter may be able to overcome resistance to microtubule binding agents. In this review article, recent developments of novel microtubule binding agents and their relevance to the treatment of hepatocellular carcinoma will be discussed.
Insights
Novel microtubule-binding agents show promise for treating liver cancer. These agents, especially when combined with mammalian target of rapamycin inhibitors, may overcome resistance and improve outcomes for hepatocellular carcinoma.
Area of Science:
- Oncology
- Cell Biology
- Pharmacology
Background:
- Microtubules are crucial in mammalian cell division and are targets for anticancer drugs.
- Microtubule-binding agents are established anticancer treatments, with newer agents offering improved specificity and resistance profiles.
- Hepatocellular carcinoma (HCC) is challenging to treat, with limited efficacy of current chemotherapies.
Purpose of the Study:
- To review recent advancements in novel microtubule-binding agents.
- To discuss the potential efficacy of these agents in treating hepatocellular carcinoma.
- To explore combination therapies, particularly with mammalian target of rapamycin inhibitors, for overcoming treatment resistance in HCC.
Main Methods:
- Literature review of recent developments in microtubule-binding agents.
- Analysis of preclinical data on the efficacy of these agents in hepatocellular carcinoma models.
- Examination of studies investigating combination therapies for HCC treatment.
Main Results:
- Newer anti-tubulin agents exhibit enhanced tumor specificity, reduced neurotoxicity, and overcome chemoresistance.
- Preclinical evidence suggests microtubule-binding agents are effective against hepatocellular carcinoma.
- Combination therapy with mammalian target of rapamycin inhibitors may overcome resistance to microtubule-binding agents in HCC.
Conclusions:
- Novel microtubule-binding agents represent a promising therapeutic avenue for hepatocellular carcinoma.
- Combination strategies involving microtubule-binding agents and mammalian target of rapamycin inhibitors warrant further investigation for HCC treatment.
- These advancements offer potential for improved outcomes in difficult-to-treat liver cancers.
Related Concept Videos
Microtubules
Microtubules
Microtubules have two structurally similar globular protein subunits: α and β tubulins. In the cytosol, the α and β tubulins form a heterodimer....
Microtubule Instability
Microtubule Formation
Destabilization of Microtubules
Microtubules in Signaling

